key: cord-1023018-5deiqs5j
authors: Castanha, Priscila M S; Tuttle, Dylan J; Kitsios, Georgios D; Jacobs, Jana L; Braga-Neto, Ulisses; Duespohl, Matthew; Rathod, Sanjay; Marti, Michelle M; Wheeler, Sarah; Naqvi, Asma; Staines, Brittany; Mellors, John; Morris, Alison; McVerry, Bryan J; Shah, Faraaz; Schaefer, Caitlin; Macatangay, Bernard J C; Methe, Barbara; Fernandez, Christian A; Barratt-Boyes, Simon M; Burke, Donald; Marques, Ernesto T A
title: IgG response to SARS-CoV-2 and seasonal coronaviruses contributes to complement overactivation in severe COVID-19 patients
date: 2022-03-10
journal: J Infect Dis
DOI: 10.1093/infdis/jiac091
sha: 1afd78c697ff03e67ca54c4323978c37c77d3902
doc_id: 1023018
cord_uid: 5deiqs5j

BACKGROUND: Excessive complement activation has been implicated in the pathogenesis of COVID-19, but the mechanisms leading to this response remain unclear. METHODS: We measured plasma levels of key complement markers, SARS-CoV-2 RNA and antibodies against SARS-CoV-2 and common cold coronaviruses (CCC) in hospitalized patients with COVID-19 of moderate (n=18) and critical severity (n=37), and healthy control subjects (n=10). RESULTS: We confirmed that complement activation is systemically increased in COVID-19 patients and is associated with a worse disease outcome. We showed that plasma levels of C1q and circulating immune complexes (CIC) were markedly increased in severe COVID-19 patients and correlated with higher IgG titers, greater complement activation and higher disease severity score. Additional analyses showed that the classical pathway was the main arm responsible for augmented complement activation in severe patients. In addition, we demonstrated that a rapid IgG response to SARS-CoV-2 and an anamnestic IgG response to the nucleoprotein of the CCC were strongly correlated with CIC levels, complement activation, and disease severity. CONCLUSIONS: These findings indicate that early, non-neutralizing IgG responses may play a key role in complement overactivation in severe COVID-19. Our work underscores the urgent need to develop therapeutic strategies to modify complement overactivation in COVID-19 patients.

A c c e p t e d M a n u s c r i p t

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in December 2019 and quickly spread throughout the globe causing the coronavirus disease 19 (COVID- 19) pandemic. Severe COVID-19 has been correlated with activation of the complement system, as indicated by the presence of low levels of C3 and high levels of the anaphylatoxin C3a, a cleavage product of C3 [1] [2] [3] [4] [5] [6] [7] [8] [9] . Recent studies have found deposits of complement factors (C1q, C4, C3, sC5-9 and B) in lung tissue [10, 11] and in the kidney [12] of severe COVID-19 patients. In addition, overactivation of the complement system has been strongly associated with higher mortality risk [4, 7, 8, 13] . Nevertheless, the mechanisms driving overactivation of the complement system in severe COVID-19 are poorly understood.

The complement system comprises a complex network of proteins, forming a highly regulated cascade of reactions. The system is activated through three pathways: the classical, the lectin and the alternative pathway. Activation of the classical pathway is mediated by the binding of C1q to immune complexes or by binding directly to pathogen surfaces. It has been hypothesized that excessive immune complexes could be the cause of overactivation of the complement system leading to severe COVID-19 [14] , but this has not yet been tested. It is well established that severe COVID-19 is correlated with a faster and more intense binding and neutralizing antibody response, however the nature and role of these antibodies in activating complement and causing severe disease have not been characterized.

Moreover, several reports indicate that a significant fraction of plasmablasts, antibodies and CD4 + T cells generated in response to SARS-CoV-2 infection are cross-reactive with the seasonal human common cold coronaviruses (CCC) [15] [16] [17] [18] [19] [20] , but the impact of these anamnestic immune response on protection and disease is not well understood.

Here we report a comprehensive analysis of the complement and antibody response to SARS-CoV-2 infection in a cohort of moderately and critically ill COVID-19 hospitalized patients. We demonstrate that systemic complement activation is highly correlated with disease severity. Our findings reveal that overactivation of the complement system is mediated by the classical pathway in response to increased levels of circulating IgG immune complexes. Antibody responses to SARS-CoV-2 develop faster and at greater levels in patients with more severe COVID-19. Importantly, we

show that antibody responses to the nucleoprotein (NP) of the CCC are boosted in more severe COVID-19 patients and that high levels of IgG anti-NP against the CCC are associated with complement activation via the classical pathway.

A c c e p t e d M a n u s c r i p t

Patients and clinical samples. The study design and data collection for the COVID-19 patients included in this study have been described elsewhere [21, 22] . Briefly, we enrolled patients with COVID-19 hospitalized at the University of Pittsburgh Medical Center Presbyterian and Shadyside hospitals (April-September 2020) in an observational study. We included 55 adult patients (≥18 years-old) that were hospitalized either in an intensive care unit (ICU) or in dedicated hospital wards (non-ICU) for COVID-19. SARS-CoV-2 infections were documented by a positive nasopharyngeal swab qPCR testing.

Demographic and clinical variables, and plasma samples were collected at post-enrollment day 1 for all patients. Prepandemic plasma samples (n=10) were obtained from healthy adults and included as controls (HC) for the complement proteins measurements. We also included samples from patients enrolled in the ongoing University of Pittsburgh ALIR (Acute Lung Injury Registry) study [23] (n=15, A c c e p t e d M a n u s c r i p t

We used linear discriminant analysis (LDA) to design a classifier for COVID-19 severity using complement markers and antibody levels. LDA classifiers were obtained using least-squares fitting, shrinkage, and equal priors. The classification errors were estimated using the error count on the training data and bolstered resubstitution estimates using Gaussian kernels [24] [25] [26] [27] . Log was applied to all features and missing values were omitted from the analysis.

All participants signed written informed consent forms for the study prior to participation. The Institutional Review Board of the University of Pittsburgh reviewed and approved all study protocols for the COVID-19 observational studies (STUDY19050099 and STUDY20040036), and for the pre-pandemic samples (STUDY19060213).

To investigate the degree of systemic complement activation, we quantified plasma levels of soluble complement proteins and their cleavage products in 55 COVID-19 patients. Baseline demographic and clinical characteristics of 37 critically ill (ICU) and 18 moderately ill (non-ICU) patients are shown in Table 1 . As expected, ICU patients presented with higher World Health Organization (WHO) 10-point ordinal scale of severity scores at admission and had higher WHO scores during the period of hospitalization. ICU patients also had significantly higher 90-day mortality than non-ICU patients (28.2% vs. 0%, p=0.005). There was no significant difference in age (p=0.161), sex (p=0.150), co-morbidities and time from symptoms onset to sample collection between non-ICU and ICU patients (p=0.235).

Plasma levels of C3 were markedly reduced in ICU patients when compared to non-ICU patients and HC, indicating increased C3 consumption in severe COVID-19 patients. C3a levels were increased in COVID-19 patients compared to HC and were ~100-fold greater in severe COVID-19 patients compared to non-ICU patients. Similarly, the ratio between C3a and C3 was markedly increased in ICU patients ( Figure 1A ). C5 levels were significantly reduced in ICU patients and the levels of C5a and C5a/C5 ratio were significantly increased in ICU when compared to non-ICU patients ( Figures 1B) . Plasma levels of sC5b-9, the activation product of the terminal complement cascade, were significantly elevated in COVID-19 patients relative to those in HC ( Figure 1C ), though no significant differences were evident based on illness severity.

A c c e p t e d M a n u s c r i p t

We next performed a ROC analysis for C3a/C3 ratio as a predictor for COVID-19 severity (Figure 2A) . A threshold for C3a/C3 ratio of ≥4.5 (log10) classified patients in high and low complement activation and provided a sensitivity and specificity for COVID-19 severity of 94.4% and 70.6%, respectively. We then analyzed the relationship between complement activation, viral RNA levels, and clinical laboratory markers of inflammation. Data on viral load was available for a total of 45 patients (n=16, non-ICU; n=29, ICU) [28] . We found that plasma levels of SARS-CoV-2 RNA were highest in patients classified as having high complement activation ( Figure 2B ). Patients with high C3a/C3 ratios also had significantly higher plasma levels of pro-inflammatory cytokines IL-6 and IL-8 ( Figure 2C ), and procalcitonin and suppression of tumorigenicity ( Figure S1 ). Levels of fractalkine, pentraxin 3, tumor necrosis factor receptor 1, and RAGE

were not associated with C3a/C3 ratios ( Figure S1 ).

We then assessed the relationship between complement activation and clinical parameters of disease severity.

High levels of complement activation were significantly associated with worse 90-day survival (log-rank p=0.0042) and

longer time to discharge from the hospital (log-rank p=0.0016; Figure 2D ). When restricted to the group of severe COVID- Collectively, these data indicate that the complement cascade is activated in COVID-19 hospitalized patients and that overactivation of the complement system is correlated with greater viral burden, increased systemic inflammation and worse disease outcomes.

We next sought to determine which arms of the system contribute to the observed overactivation of complement in severe COVID-19 patients. We first quantified markers that are specific to the initial activation steps of the alternative pathway. We observed no differences in the plasma levels of Factor D and Bb, a byproduct of Factor B cleavage, between COVID-19 patients and HC ( Figure 3A ). Subsequently, we found that plasma levels of Factor H, a regulatory protein of the alternative pathway, were increased by ~2-fold in ICU patients compared to the non-ICU patients. Factor H/ Factor D ratios, which act in antagonistic ways to influence the activation/de-activation of the alternative pathway, were higher in both non-ICU and ICU patients in comparison with HC suggesting that the alternative pathway is being suppressed in COVID-19 patients. Following, we found that plasma levels of functional mannose-binding lectin (MBL), the main recognition molecule of the lectin pathway, were similar among HC and ICU and non-ICU patients ( Figure 3B ),

indicating that this arm of the complement system is not being disproportionally activated in COVID-19 patients.

A c c e p t e d M a n u s c r i p t

We next assessed whether complement system initiation through the classical pathway accounted for the increased complement activation observed in COVID-19 patients. We observed an increase in plasma levels of total C1q in COVID-19 patients, which were significantly higher in ICU than non-ICU patients ( Figure 3C ). In addition, we found that levels of circulating immune complexes (CIC) with the ability to bind to functional C1q (CIC-C1q) were markedly increased in COVID-19 patients and were greater in ICU than non-ICU patients. Furthermore, levels of CIC-C1q were 2-fold greater in patients with high complement activation ( Figure 3D ). We found no differences in levels of functional C1 inhibitor, a plasma protease that regulates activation of the classical pathway, between COVID-19 patients and HC ( Figure 3C ).

Collectively, these findings suggest that the classical pathway is the main factor leading to the overactivation of the complement system in severe COVID-19 patients.

We subsequently analyzed the interactions between the antibody response to SARS-CoV-2 and complement activation. We first developed ELISA assays to estimate titers of binding IgG and IgA against SARS-CoV-2 structural antigens (Table S2 , Figures S2-3 ). Similar to previous reports [29] [30] [31] , we observed that severe COVID-19 patients We next investigate the degree of association between the antibody response and complement system activation.

Levels of CIC-C1q were positively correlated with binding titers of IgG against the spike and NP, and with neutralizing antibody titers to SARS-CoV-2 ( Figure 5A ), particularly in the ICU patients. Levels of CIC-C1q did not correlate with binding IgA titers, as this immunoglobulin class does not activate complement via the classical pathway. In line, the ratio of IgG/IgA binding titers was greater in ICU than non-ICU patients ( Figure 5B ). Substantiating our hypotheses of complement overactivation by the classical pathway, we also found that IgG titers were markedly increased in COVID-19

patients classified as having high levels of complement activation, while levels of IgA did not differ between groups ( Figure   5C ). Lastly, a two-dimensional LDA classifier using C3a/C3 ratio and CIC-C1q levels distinguished non-ICU and ICU patients with an error below 0.2 and with an estimated sensitivity and specificity of 73.5% and 94.4%, respectively ( Figure   A c c e p t e d M a n u s c r i p t 5D). Collectively, these data provided strong evidence that COVID-19 severity is associated with a predominant IgG response and with high levels of CIC-C1q that ultimately leads to overactivation of the complement system.

To obtain insights into the apparent rapid increase in antibody response to SARS-CoV-2 in severe COVID-19

patients, we analyzed the IgG responses to the antigenically related CCC. We developed binding assays to estimate IgG titers toward a range of spike and NP antigens of the CCC, and the spike protein of SARS-CoV. We validate our binding assays using a panel of remnants samples from a pediatric seroprevalence study (aged 1-16 years old) living in the same region as the adult COVID-19 patients [32] (Tables S3-4, Figure S4 ). The frequency of binding IgG against all CCC increased with age (Table S5) , which is consistent with endemic circulation of these viruses in the USA.

We then quantified IgG titers against CCC antigens in our COVID-19 patients. All COVID-19 patients exhibited substantial IgG reactivity to at least one of the CCC antigens (Table S6) . Notably, the increase in IgG titer to CCC antigens was more prominent in ICU than non-ICU patients and most striking against NP antigens ( Figure 6A ). We also noted an increase in IgG titers against SARS-CoV spike protein in COVID-19 patients, especially in the ICU patients. This likely reflects cross-reactive antibody responses given the structural similarities between SARS-CoV and SARS-CoV-2 [33] .

We next evaluated the relationship between antibody binding to CCC and complement activation and found that IgG titers to NP antigens ( Figure 6C ) but not to the spike ( Figure 6B ) were greater among patients classified as having high complement activation. In addition, COVID-19 patients displayed a significant positive correlation between levels of CIC-C1q and IgG titers against NP antigens for all CCC ( Figure 6D ). This correlation was not significant when stratifying patients by disease severity. Collectively, these findings reveal a cross-reactive anamnestic response to CCC in COVID-

M a n u s c r i p t

We show that IgG responses against SARS-CoV-2 and the CCC are associated with complement activation in severe COVID-19 patients. In line with earlier reports [1, [6] [7] [8] [9] , we confirm that markers of systemic complement activation are significantly increased in severe COVID-19 patients and distinguish those with worse disease outcomes. More importantly, our in-depth analysis of pathway-specific components delineate the role of the classical pathway in the enhanced complement activation observed in severe COVID-19 patients and suggests a previously unrecognized mechanism of antibody-mediated activation driven by an overexuberant IgG response against SARS-CoV-2 and CCC antigens. These data indicate that an immune dysregulation of both the innate and adaptive immune systems is a primary feature of COVID-19 severity.

Our data showed that high complement activation is associated with some established markers of inflammation commonly elevated in severe COVID-19 patients [34, 35] . This is consistent with a hyperinflammatory milieu characteristic of SARS-CoV-2 pathophysiology, which is likely influenced by the enhanced levels of the potent anaphylatoxins C3a and C5a, particularly in ICU patients [6, 8] . In contrast with a prior report [1] , our findings indicate that complement overactivation correlates with levels of SARS-CoV-2 RNA in the plasma. This discrepancy between studies might be related to the sensitivity of the assays used for detection of viral RNA. SARS-CoV-2 RNA in our patients was measured using an ultrasensitive qRT-PCR method resulting in a greater proportion of RNAemia-positive ICU patients than previously described [28] .

While earlier reports indicate that overactivation of the complement system plays a critical role in COVID-19

immunopathology [1, [5] [6] [7] [8] [9] [10] , our detailed analysis of several pathway-specific markers extend these findings by revealing that the classical pathway and the humoral response are associated with unfavorable COVID-19 outcomes. The high levels of CIC-C1q seen in our patients are likely due to the presence of greater amounts of antigens and antibodies present in the circulation, to reduced CIC clearance, or both. Earlier reports have shown extensive deposition of C1q and C4d, a marker of complement activation by CIC, in postmortem lung sections of COVID-19 patients [10, 36] . Complement activation by CIC has also been associated with the pathophysiology of other respiratory viruses [37, 38] . Interestingly, a prior in vitro study reported no C1q binding when mixing SARS-CoV-2 proteins with non-immune human serum, indicating that the classical pathway is not activated in the absence of specific antibodies [39] . Of note, the assay used in our study measures CIC with the ability to bind to functional C1q and thus activate the complement systema feature that is further confirmed by the association between levels of CIC-C1q and C3a/C3 ratio seen in our patients. In addition, it is important to mention that CIC can also induce a complement-independent dysregulated inflammatory milieu via CIC engagement to A c c e p t e d M a n u s c r i p t FcγR, leading to excessive activation of alveolar macrophages that likely contributes to amplification of the proinflammatory cytokine release seen in severe COVID-19 patients [40, 41] .

Consistent with earlier reports [29] [30] [31] , our analysis of the magnitude of the antibody response to SARS-CoV-2 suggest that ICU patients seroconvert earlier and developed higher titers of binding IgG and IgA and neutralizing antibodies than patients with moderate disease. Interestingly, patients with higher IgG/IgA ratio had more severe disease, which is consistent with the greater capacity of IgG to mediate complement activation. Severe COVID-19 patients also displayed a strong rise in the levels of IgG against the NP of CCC, which is in agreement with recent reports showing that

IgG antibodies and B cell clones targeting structural antigens of the CCC are boosted upon SARS-CoV-2 infection [20, 42, 43] . Extending on these findings, our data reveal a marked correlation between enhanced complement activation by CIC-C1q and IgG levels to SARS-CoV-2 and CCC. These findings suggest that overactivation of the complement system by CIC at the pulmonary and systemic levels may contribute to the secretion of pro-inflammatory cytokines, immune cell recruitment, and complement deposition within the lung, in a mechanism similar to the antibody-mediated enhanced respiratory disease observed in other respiratory viruses [38, 44] .

Since activation markers of the alternative and the lectin pathways were present at similar levels, we were unable to ascribe their role in the observed complement overactivation seen in our COVID-19 patients. However, this does not exclude the possibility that these arms of the complement system also contribute to COVID-19 severity. Earlier reports have shown the ability of MBL to bind SARS-CoV-2 proteins and activate complement [39, 45] , suggesting that the lectin pathway is possibly involved in complement activation in COVID-19. Activation of the alternative pathway has also been implicated in COVID-19 pathogenesis using in vitro systems and in clinical studies [9, 46, 47] . Interestingly, recent reports have suggested that activation of the alternative pathway in SARS-CoV-2 infected patients is Factor D-independent [9, 46] . This is to some extent consistent with our data showing no differences in Factor D levels between COVID-19 patients and HC. Notably, negative regulatory mediators of the alternative pathway (e.g., Factor H) were markedly upregulated in our patients, suggesting that this pathway is being suppressed rather than synergistically amplifying complement activation in COVID-19. This variability among studies may result from differences in timing of sample collection, type of sample tested (plasma EDTA, citrate and serum), and sensitivity of the methods used for complement measurements. However, based on available data, it is reasonable to hypothesize that SARS-CoV-2 infection triggers activation of the complement cascade via all three pathways and that the classical pathway likely contributes the most to overactivation of the system and hence disease severity.

A c c e p t e d M a n u s c r i p t

We acknowledge that the number of subjects included in our analysis was relatively small which might underpower some of the conclusions. In addition, all patients enrolled in our cohort were hospitalized, and complement activation and antibody response in asymptomatic or mild COVID-19 cases could not be assessed in this study. More extensive studies are needed to clearly elucidate the mechanistic basis by which SARS-CoV-2 mediates excessive activation of the complement system, ideally with longitudinal sampling throughout the course of the disease, including samples from mild COVID-19 cases and from patients that develop moderate symptoms and later progress to severe disease.

In summary, our findings highlight the role of the classical pathway in mediating complement overactivation in in CIC-C1q between patients classified as having low (C3a/C3 ratio <4.5 log10) and high (C3a/C3 ratio ≥4.5 log10) complement activation. Each symbol in the scatter plots represents an individual patient and horizontal line is the median.

Statistical significance is determined using Kruskal-Wallis 1-way ANOVA ( ### p<0.001, #### p<0.0001) and Mann-Whitney U test (*p<0.05, **p<0.01, *** p<0.001, **** p<0.0001). A c c e p t e d M a n u s c r i p t in ICU wards with respiratory illness not related to SARS-CoV-2 infection were included as a group for comparisons (non-COVI ICU, n=20). Scatter plots of the differences in plasma titers of binding IgG against the spike of CCC and SARS-CoV (B) and against the NP (C) of the CCC, stratified by the C3a/C3 ratio as low (C3a/C3 ratio <4.5 log10) and high (C3a/C3 ratio ≥4.5 log10) complement activation. Each symbol in the scatter plots represents an individual patient and horizontal line is the median. Statistical significance is determined using A c c e p t e d M a n u s c r i p t 

The authors declared the following conflict of interest: Dr. Braga-Neto reports grants from NSF, and Texas A&M Vice-President of Research

and Janssen Pharmaceuticals; serves or has served as a consultant for Gilead Sciences, Inc., Accelevir Diagnostics, and Xi'an Yufan Biotechnologies; owns shares options in Co-Crystal Pharmaceuticals, Inc., and Infectious Diseases Connect; and is a shareholder of Abound Bio, Inc. His holdings in Co-Crystal Pharmaceuticals

Morris reports grants from NIH/NHLBI and NIH/NIAID during the conduct of the study

McVerry reports grants from Bayer Pharmaceuticals, Inc., the Translational Breast Cancer Research Consortium, and the UPMC Learning While Doing Program, during the conduct of the study

Shah reports grants from NIH/ NIGMS during the conduct of the study

Macatangay reports grants from NIH and Gilead Sciences

Burke reports leadership roles as President and Board Chair of Epistemix, Inc., Director of Magee Women's Research Institute, and Member, Board of Health, of Allegheny County, unrelated to this work; and is a shareholder of

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study

Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection

Risk Factors for Mortality of COVID-19 Patient Based on Clinical Course: A Single Center Retrospective Case-Control Study. Front Immunol

Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state

Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes

Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. Front Immunol

Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality. Front Immunol

Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection

Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients

Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement

Abnormal immunity of non-survivors with COVID-19: predictors for mortality

COVID-19 as an Immune Complex Hypersensitivity in Antigen Excess Conditions: Theoretical Pathogenetic Process and Suggestions for Potential Therapeutic Interventions. Front Immunol

Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Comprehensive mapping of immune perturbations associated with severe COVID-19

Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19

COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome: Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes

Biomarker-Based Classification of Patients With Acute Respiratory Failure Into Inflammatory Subphenotypes: A Single-Center Exploratory Study

e0518. Available from

Increased Alternative Complement Pathway Function and Improved Survival during Critical Illness

Scikit-Learn: Machine Learning in Python

Error Estimation for Pattern Recognition

SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

seroprevalence during mitigation procedures in Southwestern Pennsylvania

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect

Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes

A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease

Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins. Front Immunol [Internet

Circulating multimeric immune complexes drive immunopathology in COVID-19

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Immunological imprinting of the antibody response in COVID-19

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv

SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation

We thank all the clinical staff at the University of Pittsburgh Medical Center Presbyterian and Shadyside Hospital units for coordinating patient enrollment and specimen collection. We also thank Dr. Willian Bain for assistance with collection of patient samples. This study was supported in part by the pilot COVID-19 awards received from the University of 

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t

Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition.